Sionna Therapeutics Inc. (SION)
NASDAQ: SION
· Real-Time Price · USD
17.41
1.57 (9.91%)
At close: Jun 30, 2025, 3:59 PM
17.35
-0.34%
After-hours: Jun 30, 2025, 05:51 PM EDT
Company Description
Sionna Therapeutics, Inc. is a biopharmaceutical company.
The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Sionna Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive Suite 500 Waltham, Massachusetts United States | |
| Website | https://www.sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002036042 |
| CUSIP Number | n/a |
| ISIN Number | US8294011080 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan M.B.A. | President, Chief Executive Officer & Director |
| Elena H. Ridloff C.F.A. | Chief Financial Officer & Head of Corporate Development |
| Jennifer Fitzpatrick J.D. | Chief Legal Officer |
| Vanya Sagar | Chief People Officer |
| Andy Chu | Vice President of Information & Technology |
| Dr. Charlotte McKee M.D. | Chief Medical Officer |
| Dr. Greg Hurlbut Ph.D. | Co-Founder & Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder & Senior Vice President of Medicinal Chemistry |
| Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs & Quality |
| Meghan Bagshaw | Vice President of Programs, Portfolio & Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | 4 | Filing |
| Jun 16, 2025 | SCHEDULE 13G | Filing |